Home>>Analytical Standards>>(±)-Atenolol-d7

(±)-Atenolol-d7 (Synonyms: (R,S)-Atenolol-d7, Duraatenol, ICI 66082)

Catalog No.GC46273

An internal standard for the quantification of (±)-atenolol

Products are for research use only. Not for human use. We do not sell to patients.

(±)-Atenolol-d7 Chemical Structure

Cas No.: 1202864-50-3

Size Price Stock Qty
1 mg
$45.00
In stock
5 mg
$195.00
In stock
10 mg
$324.00
In stock
25 mg
$573.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(±)-Atenolol-d7 is intended for use as an internal standard for the quantification of (±)-atenolol by GC- or LC-MS. (±)-Atenolol is an antagonist of the β1-adrenergic receptor (β1-AR; Ki = 1.14 µM).1 It is selective for β1-ARs over β2-ARs (Ki = 48.7 µM). (±)-Atenolol (200 mg/kg per day) delays the onset of hypertension in spontaneously hypertensive rats.2 Formulations containing atenolol have been used in the treatment of high blood pressure.

1.Golf, S., Bjornerheim, R., Erichsen, A., et al.Relative selectivity of different β-adrenoceptor antagonists for human heart β1- and β2-receptor subtypes assayed by a radioligand binding techniqueScand. J. Clin. Lab. Invest.47(7)719-723(1987) 2.Richer, C., Boissier, J.R., and Giudicelli, J.F.Chronic atenolol treatment and hypertension development in spontaneously hypertensive ratsEur. J. Pharmacol.47(4)393-400(1978)

Reviews

Review for (±)-Atenolol-d7

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (±)-Atenolol-d7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.